Korro Bio
Korro Bio utilizes its proprietary Oligonucleotide Promoted Editing of RNA (OPERA®) platform to precisely edit RNA by modifying single nucleotides, thereby modulating biological pathways. This technology aims to provide therapeutic benefits for genetic disorders, such as Alpha-1 Antitrypsin Deficiency (AATD), caused by specific mutations in the SERPINA1 gene.
- Biotechnology
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Many genetic disorders, such as Alpha-1 Antitrypsin Deficiency (AATD), are caused by single nucleotide mutations within genes, leading to dysfunctional proteins and associated health complications. Current treatment options often fail to address the root cause of these diseases.
Solution
Korro Bio is developing RNA editing therapeutics using its proprietary Oligonucleotide Promoted Editing of RNA (OPERA®) platform. The OPERA® platform is designed to precisely correct single nucleotide mutations in RNA, thereby modulating biological pathways and restoring normal protein function. This approach redirects a naturally occurring editing process within cells by delivering a chemically modified RNA that targets the specific change needed. By addressing the underlying genetic cause of disease, Korro Bio aims to provide therapeutic benefits for a range of genetic disorders.
Target Audience
The primary target audience includes patients suffering from genetic disorders caused by single nucleotide mutations, as well as healthcare providers and researchers focused on developing and implementing novel genetic medicines.
Features
- OPERA® platform for precise single nucleotide editing of RNA
- Chemically modified RNA delivery for targeted editing
- Potential to repair proteins caused by genetic mutations
- Ability to alter proteins to activate a biological pathway
- Versatility to address a broad range of rare and prevalent diseases